Search Results - "Buka, Richard J."

Biomarkers in Human Anaphylaxis: A Critical Appraisal of Current Evidence and Perspectives by Beck, Sarah C, Wilding, Thomas, Buka, Richard J, Baretto, Richard L, Huissoon, Aarnoud P, Krishna, Mamidipudi T

“…Anaphylaxis is a type I hypersensitivity reaction that is potentially fatal if not promptly treated. It is a clinical diagnosis, although measurement of serial…”
Get full text

Fatal drug reaction to andexanet alfa: a case report by Buka, Richard J., Krishna, Mamidipudi T., Sutton, David J.

“…Andexanet alfa is a recombinant, modified factor Xa (FXa) molecule that is used for the reversal of the anticoagulant effect of oral anti‐FXa anticoagulants in…”
Get full text

How will UK hospitals use andexanet alfa? A review of local protocols by Glancy, Paula, Sutton, David J., Gomez, Keith, Nicolson, Phillip L. R., Buka, Richard J.

“…TABLE 1 Contents of protocols in relation to National Institute for Health and Care Excellence (NICE) recommendations and inclusion and exclusion criteria for…”
Get full text

UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease by Buka, Richard J, Roy, Noémi, Nicolson, Phillip LR

“…Crizanlizumab was recommended for use in patients with sickle cell disease in the UK in October 2021 and received widespread media coverage. Accuracy of…”
Get full text

Anti-platelet factor 4 immunothrombotic syndromes by Buka, Richard J, Pavord, Sue

“…Anti-platelet factor 4 immunothrombotic syndromes comprise a group of disorders that include heparin-induced thrombocytopenia and vaccine-induced immune…”
Get full text

HaemSTAR—Growing Experience From a National, Trainee‐led Research Network by Wilson, Lydia, Doyle, Andrew J., Millen, Emily, Bull, Tom, Biss, Tina, Hart, Dan, Lowe, Gillian, Toh, Cheng‐Hock, Buka, Richard J., Nicolson, Phillip L. R.

Get full text

DOACs for VTE in patients with brain cancer and brain metastases: choices, choices, choices by Buka, Richard J., Sutton, David J.

Get full text

Heterozygous, germline JAK2 E846D substitution as the cause of familial erythrocytosis by Tun, Phyo Wint Wint, Buka, Richard J., Graham, Jane, Dyer, Peter

Get full text

Cancer is not a single disease: is it safe to extrapolate evidence from trials of direct oral anticoagulants in cancer‐associated venous thromboembolism to patients with haematological malignancies? by Buka, Richard J., Chandra, Deepak, Sutton, David J.

Get full text

PF4 activates the c-Mpl-Jak2 pathway in platelets by Buka, Richard J, Montague, Samantha J, Moran, Luis A, Martin, Eleyna M, Slater, Alexandre, Watson, Steve P, Nicolson, Phillip L R

“…Platelet factor 4 (PF4) is an abundant chemokine that is released from platelet α-granules on activation. PF4 is central to the pathophysiology of…”
Get full text

Enoxaparin is not an oral factor Xa inhibitor. Response to Sutton et al. real-world clinical outcomes among US veterans with oral factor Xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate by Buka, Richard J, Sutton, David J, Nicolson, Phillip LR

Get full text

Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2, and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand by Martin, Eleyna M, Clark, Joanne C, Montague, Samantha J, Morán, Luis A, Di, Ying, Bull, Lily J, Whittle, Luke, Raka, Florije, Buka, Richard J, Zafar, Idrees, Kardeby, Caroline, Slater, Alexandre, Watson, Steve P

“…Clustering of the receptors glycoprotein receptor VI (GPVI), C-type lectin-like receptor 2 (CLEC-2), low-affinity immunoglobulin γ Fc region receptor II-a…”
Get full text

Corrigendum to ‘Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2 and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand’: Journal of Thrombosis and Haemostasis, Volume 22, Issue 1, (January 2024) Pages 271-285 by Martin, Eleyna M., Clark, Joanne C., Montague, Samantha J., Morán, Luis A., Di, Ying, Bull, Lily J., Whittle, Luke, Raka, Florije, Buka, Richard J., Zafar, Idrees, Kardeby, Caroline, Slater, Alexandre, Watson, Steve P.

Get full text

Anaphylaxis and Clinical Utility of Real-World Measurement of Acute Serum Tryptase in UK Emergency Departments by Buka, Richard J., Knibb, Rebecca C., Crossman, Richard J., Melchior, Cathryn L., Huissoon, Aarnoud P., Hackett, Scott, Dorrian, Susan, Cooke, Matthew W., Krishna, Mamidipudi T.

“…British guidelines recommend that serial acute serum tryptase measurements be checked in all adults and a subset of children presenting with anaphylaxis. This…”
Get full text

Characterisation Of Anaphylaxis In a Large UK City With An Ethnically Diverse Population by Buka, Richard J, Crossman, Richard J, Derbridge, Cathryn, Huissoon, Aarnoud P, Hackett, Scott, Cooke, Matthew W, Dorrian, Susan, Krishna, Mamidipudi T

Get full text

Andexanet alfa: trials just leave us with more questions by Buka, Richard J.

Get full text

Corrigendum to ‘Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2 and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand’ by Martin, Eleyna M., Clark, Joanne C., Montague, Samantha J., Morán, Luis A., Di, Ying, Bull, Lily J., Whittle, Luke, Raka, Florije, Buka, Richard J., Zafar, Idrees, Kardeby, Caroline, Slater, Alexandre, Watson, Steve P.

Get full text

Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thrombosis by Akbulut, Asim Cengiz, Arisz, Ryanne A, Baaten, Constance C F M J, Baidildinova, Gaukhar, Barakzie, Aarazo, Bauersachs, Rupert, Ten Berg, Jur, van den Broek, Wout W A, de Boer, H C, Bonifay, Amandine, Bröker, Vanessa, Buka, Richard J, Ten Cate, Hugo, Ten Cate-Hoek, Arina J, Cointe, S, De Luca, Ciro, De Simone, Ilaria, Diaz, Rocio Vacik, Dignat-George, Françoise, Freson, Kathleen, Gazzaniga, Giulia, van Gorp, Eric C M, Habibi, Anxhela, Henskens, Yvonne M C, Iding, Aaron F J, Khan, Abdullah, Koenderink, Gijsje H, Konkoth, Akhil, Lacroix, Romaric, Lahiri, Trisha, Lam, Wilbur, Lamerton, Rachel E, Lorusso, Roberto, Luo, Qi, Maas, Coen, McCarty, Owen J T, van der Meijden, Paola E J, Meijers, Joost C M, Mohapatra, Adarsh K, Nevo, Neta, Robles, Alejandro Pallares, Poncelet, Philippe, Reinhardt, Christoph, Ruf, Wolfram, Saraswat, Ronald, Schönichen, Claudia, Schutgens, Roger, Simioni, Paolo, Spada, Stefano, Spronk, Henri M H, Tazhibayeva, Karlygash, Thachil, Jecko, Vallier, L, Veninga, Alicia, Verhamme, Peter, Visser, Chantal, Watson, Steve P, Wenzel, Philip, Willems, Ruth A L, Willers, Anne, Zhang, Pengyu, Zifkos, Konstantinos, van Zonneveld, Anton Jan

“…The Fourth Maastricht Consensus Conference on Thrombosis included the following themes. Theme 1: The "coagulome" as a critical driver of cardiovascular…”
Get more information

Corrigendum to 'Trivalent nobody-based ligands mediate powerful activation of GPVI, CLEC-2 and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand': Journal of Thrombosis and Haemostasis, Volume 22, Issue 1, (January 2024) Pages 271-285 by Martin, Eleyna M, Clark, Joanne C, Montague, Samantha J, Morán, Luis A, Di, Ying, Bull, Lily J, Whittle, Luke, Raka, Florije, Buka, Richard J, Zafar, Idrees, Kardeby, Caroline, Slater, Alexandre, Watson, Steve P

Get full text

Heterozygous, germline JAK2 E846D substitution as the cause of familial erythrocytosis by Tun, Phyo Wint Wint, Buka, Richard J, Graham, Jane, Dyer, Peter

Get full text